»
IN BRIEF
INDIAN IT GIANT SETTING UP IRISH SOFTWARE DELIVERY CENTRE
HCLTechnologies, one of the largest ITcompanies in India, is to establish a software delivery centre inDublin, creating 80 jobs over three years for ITgradu- ates. The new centre will serviceHCL
clients and prospects in the finan- cial services, insurance and health- care/pharmaceutical industries. The company, an IDA client, had
US$3.5bn revenues in the year end- ing June 2011 and employs over 85,000 people in 31 countries, in- cluding 4,500 people across Eu- rope. It has already established global delivery centres inUK, Poland, Finland,US, Brazil, China, India,Malaysia andNorthern Ire- land. “This facility, with its specialist
skills in software development in- cludingmultilingual talent and proximity to our European cus- tomers, will add significant value to our global deliverymodel from which we can provide on- and off- shore support tomeet their specificrequirements,” said Rajeev Sawhney, president forHCL Eu- rope. IDA Ireland CEO Barry O’Leary
saidHCL had been amajor target for the agency since it had estab- lished an office in India. “HCL is one of the biggest brand names in the Indian IT sector and IDA is confident that this will be a catalyst for further projects fromIndian multinational companies to estab- lish operations in Ireland,” he said.
€57M LIFE SCIENCES R&D INSTITUTE OPENED
The€57mNational Institute for BioprocessingResearch and Training (NIBRT) has been offi- cially opened. The state-of-the- art facilitywill focus on educating skilledworkers and ground-breaking research col- laborations. The 6,500 sq metre facility rep-
resents a major strategic invest- ment in the bioprocessing industry in Ireland and is a collaboration be- tween higher-education institutes - University College Dublin, Trinity College Dublin, Institute of Tech- nology, Sligo, and Dublin City Uni- versity – with support fromthe Irish Government and IDA Ireland. It is the only bioprocessing train-
ing facility in the world that so closely replicates an industrial bio- processing environment. This al- lows trainees the opportunity to learn and practise complex techni- cal bioprocessing procedures and to enhance their skills using the most modern equipment and facili- ties available anywhere. “The pharmaceutical industry
plays a critical role in the economic well-being of Ireland and the new NIBRT facility sets Ireland apart as a world-class location for these companies,” said Seán Sherlock TD, Minister for Research and In- novation, who opened the institute.
An Taoiseach EndaKenny TD and Sara Mathews, chairman and CEO,Dun& Bradstreet
D&B EXPANDING DUBLIN PRESENCE
Further to establishing its presence in Dublin over a year ago, business information specialist Dun & Brad- street (D&B) is to create an addi- tional 75 jobs by 2012, bringing total employment in Ireland to 225. D&Bcurrently employs 150 people in
highly skilled roles in Sandyford, Co Dublin. A 170-year-old company inter- nationally, its Dublin-based operation serves customers through a range of technology and operations functions. The centre is responsible for the col- lection and processing of data on sub- ject companies. D&B has in-sourced operations roles fromexisting off-shore arrangements and many of these roles have been filled in Dublin. “D&B’s operation in Ireland has sur-
passed the company’s expectations and has resulted in more highly skilled roles being created than previously an- ticipated,” said An Taoiseach Enda Kenny TD. “The company’s decision to ramp up its recruitment is very wel- come news and is a strong endorse- ment of Ireland’s reputation as a leading location for the international business information products and services sector.”
GENZYME OPENS €150M EXPANSION ATWATERFORD BIOTECH CAMPUS
Genzyme has officially inaugurated a €150m expansion at its biotechnology campus inWaterford. The biotechnology site employing 500
people has seen capital investment of €500msince Genzyme’s arrival in Ireland
10 years ago. Themost recent investment has increased capacity at the company’s manufacturing operation, accompaniedby additional development capability, labora- tory facilities and administration offices. “Waterfordisastrategicsitewithin Gen-
12 INNOVATION IRELAND REVIEW Issue 3 Autumn/Winter 2011
zymeandproducts fromthis locationmake a great difference in the lives of patients in more than 70 countries,” said Christopher AViehbacher,CEO,Sanofi, speakingonhis first visit to Ireland since Sanofi’s acquisi- tion ofGenzyme earlier this year.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80